BOYERTOWN, PA, United States
BOYERTOWN, PA, United States

Time filter

Source Type

News Article | May 10, 2017
Site: www.businesswire.com

OCALA, Fla.--(BUSINESS WIRE)--REV Group (NYSE: REVG), a $2+ billion manufacturer of industry-leading specialty vehicle brands and leading provider of parts and services, is pleased to announce Premier Fire Apparatus, as an E-ONE brand dealership in targeted regions of New York. Premier Fire Apparatus will serve as the exclusive dealership of E-ONE trucks for both sales and service for the New York counties of Albany, Columbia, Delaware, Dutchess, Fulton, Greene, Montgomery, Orange, Otsego, Putnam, Rensselaer, Rockland, Saratoga, Schenectady, Schoharie, Sullivan, Ulster, and Westchester. This spring, Premier Fire Apparatus Owner, Ken Finke, acquired a former E-ONE dealership. Ken brings over 40 years of fire industry experience, and has served as Fire District Commissioner, Fire Department Chief, and fire fighter. He is an active member of the Cornell Hook & Ladder Fire Company in New Baltimore and has served on several truck purchasing committees. “I know how important it is to have the right tools for the job, including the right piece of equipment that is designed to allow fire fighters to do their job safely,” Ken Finke says. “As an E-ONE Dealer, I am fully committed with an emphasis on customer service. " "We are pleased to have Premier Fire Apparatus on board as an E-ONE dealer serving our New York Customers,” says E-ONE Key Account Manager Alan Hollister. “Ken's business acumen as well as his history of success will make him a valued asset to the fire service industry. With the addition of Premier Fire, the E-ONE dealer network continues to grow, providing further capabilities and support for our customers." Premier Fire Apparatus is located at 1564 Route 9G Hyde Park, NY 12538. To contact Premier, email kfinke@premierfireapp.com or call 845-229-6041. REV (NYSE: REVG) is a leading designer, manufacturer and distributor of specialty vehicles and related aftermarket parts and services. We serve a diversified customer base primarily in the United States through three segments: Fire & Emergency, Commercial and Recreation. We provide customized vehicle solutions for applications including: essential needs (ambulances, fire apparatus, school buses, mobility vans and municipal transit buses), industrial and commercial (terminal trucks, cut-away buses and street sweepers) and consumer leisure (recreational vehicles (“RVs”) and luxury buses). Our brand portfolio consists of 27 well-established principal vehicle brands including many of the most recognizable names within our served markets. Several of our brands pioneered their specialty vehicle product categories and date back more than 50 years. Investors-REVG


News Article | May 16, 2017
Site: co.newswire.com

Advanced HVAC is celebrating their 10th anniversary of business success in Ottawa. Founded as a modest, family-owned business, Advanced HVAC has more than doubled in size over the past decade, continuing to experience growth and success through a dedication to premium craftsmanship and client satisfaction. “Over the past 10 years, our company philosophy has remained the same. As a family-owned and operated business, we have strong community values that guide every interaction with our customers,” said David Laplante, Owner, Advanced HVAC. “We offer exceptional service for our clients because we care. This includes our 24-hour emergency response service, 365 days a year, and some of the best product and service warranties on the market.” Advanced HVAC offers a full spectrum of professional services in heating and cooling, including installation, repair, and maintenance services for your furnace, air conditioner, and water heater. Advanced HVAC also offers air purifier installation for the home to ensure you and your family are experiencing the cleanest, healthiest air possible. “Premium air quality and HVAC energy-efficiency have become increasingly dominant concerns for homeowners across Ottawa in recent years. Using the latest HVAC products and technologies, we ensure your home is running effectively and efficiently, positively impacting your monthly utility bill and your health,” said David Laplante. “We provide customized solutions for each homeowner, identifying the best products and systems to suit your home and your budget.” Each HVAC technician on the Advanced HVAC team is highly qualified, fully licensed, trained and specialized in all aspects of the trade. Advanced HVAC is registered and quality assessed with the Technical Standards and Safety Authority (TSSA). Advanced HVAC is also A+ accredited with the Better Business Bureau (BBB), BAXI certified and members of HRAI and OCA. Advanced HVAC services the Ottawa area, including Orleans, Nepean, Rockland, Navan, Embrun, Russell, Limoges, Casselman, Manotick, and Kanata. To get a quote on Ottawa HVAC services, contact Advanced HVAC today. Advanced HVAC is a medium-sized family-operated heating and cooling company serving the Ottawa and surrounding areas. Advanced HVAC offers a variety of products backed by the best warranties in the industry. They provide fast and efficient 24-hour emergency HVAC service in Ottawa, 365 days of the year. The company has over 100 years of combined HVAC experience. One of their detail-oriented, dedicated, and talented heating and cooling technicians is ready to assist you today.


News Article | May 15, 2017
Site: www.prweb.com

NES Financial, a Silicon Valley FinTech company providing technology-enabled solutions for efficient back and middle office administration of complex financial transactions, recently added senior executives Eric Weinstein and Chet Hayman to its sales organization. Both will report to Senior Vice President of Sales, Christian Lyndes. Weinstein joins the Company from Conifer Financial Services where he was Director of Development, Fund Services. His prior experience includes Vice President of Business Development and Marketing at Vastardis Capital Services. Weinstein will be based in New York City. Hayman joins the Company from Satuit Technologies, where he was Senior Vice President of Sales. His prior experience includes senior roles in sales and finance at Oracle Corporation, First Union Securities, and UBS. Hayman will be based in the Boston area, working out of the Company’s Rockland, MA office. “With our unique solutions and the rapid growth we are seeing in private equity, it was incumbent upon us to tap executives like Eric and Chet that blend technology sales and financial services expertise,” said Lyndes. “Their backgrounds and experience fit right in with our company and will immediately be valuable additions to the Sales team.” On what set NES Financial apart from other service providers, Weinstein said, “NES Financial is uniquely positioned to meet the needs of today’s private equity fund managers and investors with a next-generation third-party fund administration solution.” Added Hayman, “The combination of Silicon Valley technology prowess and Big Four accounting acumen sets NES Financial apart from other firms in the private equity fund administration space.” The Company’s innovative Private Equity Administration Solution provides a fully integrated, scalable, and cost-effective technology platform for third-party fund administration. Designed to help private equity firms raise capital faster, the solution reduces operational risk by improving compliance and data security, creating greater transparency and service to limited partners, and using data analytics to generate valuable business intelligence for general partners. About NES Financial NES Financial is a Silicon Valley financial technology (FinTech) company providing technology-enabled solutions and services for the efficient back and middle office administration of complex financial transactions. Serving private equity, commercial real estate, and Fortune 1000 clientele, we offer industry-leading fund administration, loan servicing, specialized EB-5 administration, and 1031 tax deferred exchange services. Our unwavering commitment to data security, operational redundancy, and compliance reporting is evidenced by 11 consecutive years of successful independent audits of our technology, processes, and financial controls. Today, NES Financial services over 190 funds, administers over $75B of 1031 transactions annually, and has worked with over 550 EB-5 projects. For more information, visit NES Financial.


News Article | April 27, 2017
Site: globenewswire.com

* Constant currency revenue, core revenue, non-GAAP EPS, non-GAAP gross margin and non-GAAP net income (referenced below) are non-GAAP financial measures. A reconciliation of these and other non-GAAP financial measures used in this release to their most directly comparable GAAP financial measure is included under the heading “Non-GAAP Financial Measures” below. SOUTH JORDAN, Utah, April 27, 2017 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology and endoscopy, today announced sales of $171.1 million for the quarter ended March 31, 2017, an increase of 23.9% over sales of $138.1 million for the quarter ended March 31, 2016.  On a constant currency basis, sales for the first quarter of 2017 would have been up 24.8% over sales for the comparable quarter of 2016. Merit’s GAAP net income for the first quarter of 2017 was $14.8 million, or $0.32 per share, compared to $4.4 million, or $0.10 per share, for the first quarter of 2016. GAAP net income for the first quarter of 2017 included a bargain purchase gain of approximately $12.2 million, or $0.27 per share pre-tax, which Merit recognized as a result of its acquisition of the critical care division of Argon Medical Devices, Inc., and approximately $(4.8) million, or $(0.11) per share pre-tax, of legal expenses Merit incurred in responding to the pending subpoena from the Department of Justice.  Merit’s non-GAAP net income* for the quarter ended March 31, 2017 was $12.7 million, or $0.28 per share, compared to $8.3 million, or $0.19 per share, for the quarter ended March 31, 2016. Given the circumstances of the Argon acquisition, which closed during the first quarter of 2017, and the complexity of the transaction, the entire purchase price allocation for the transaction (as well as the gain on bargain purchase) is considered provisional at this time and is subject to adjustment to reflect new information obtained about factors and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date, while the measurement period remains open. Merit’s sales by category for the three months ended March 31, 2017, compared to the corresponding period in 2016, were as follows: “Our management team is pleased with our performance during the first quarter, especially with the activities involved in the integration of the acquisitions of DFINE, the critical care division of Argon and the assets of Catheter Connections,” said Fred P. Lampropoulos, Merit’s Chairman and Chief Executive Officer.  “We delivered strong revenue growth across all sales divisions in the first quarter.” “We continue to focus on our promised deliverables, revenue growth, gross margin expansion, our R&D pipeline, and discipline in controlling our SG&A expenses,” Lampropoulos said. “We plan to deliver a two-year extension of our three-year plan following the second quarter of 2017,” Lampropoulos added.  “We reaffirm our revenue guidance of $713-$723 million and non-GAAP earnings of $1.15-$1.20 per share for the year ending December 31, 2017, without reduction due to our recent public stock offering.  Our guidance on GAAP EPS for the year ending December 31, 2017 is updated from $0.54-$0.60 to $0.80-$0.86 to reflect the bargain purchase gain recognized from the Argon acquisition.” 2017 GUIDANCE Based upon information currently available to Merit's management, Merit estimates that for the year ending December 31, 2017, absent material acquisitions or non-recurring transactions, Merit's revenues will be in the range of $713-$723 million, an increase of approximately 18-20%, compared to revenues of $603.8 million for the year ended December 31, 2016.  Also, based on information currently available to Merit's management, Merit estimates that, absent material acquisitions or non-recurring transactions, Merit's GAAP earnings per share for 2017 will be in the range of $0.80-$0.86 and non-GAAP* earnings per share for 2017 will be in the range of $1.15-$1.20. Merit’s financial guidance for the year ending December 31, 2017 is subject to risks and uncertainties, including, but not limited to, potential accounting adjustments attributable to Merit’s ongoing valuation of intangibles and other financial assets acquired from Argon Medical Devices, Inc. and Catheter Connections, Inc., as well as risks and uncertainties identified in Merit’s public filings. CONFERENCE CALL Merit will hold its investor conference call (conference ID 1848749) today, Thursday, April 27, 2017, at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific).  The domestic telephone number is (844) 578-9672, and the international number is (508) 637-5656.  A live webcast will also be available for the conference call at www.merit.com/investors. Non-GAAP Financial Measures Although Merit’s financial statements are prepared in accordance with accounting principles which are generally accepted in the United States of America (“GAAP”), Merit’s management believes that certain non-GAAP financial measures referred to in this release provide investors with useful information regarding the underlying business trends and performance of Merit’s ongoing operations and can be useful for period-over-period comparisons of such operations.  Non-GAAP financial measures used in this release include: Merit’s management team uses these non-GAAP financial measures to evaluate Merit’s profitability and efficiency, to compare operating results to prior periods, to evaluate changes in the operating results of its operating segments, and to measure and allocate financial resources internally. However, Merit’s management does not consider such non-GAAP measures in isolation or as an alternative to such measures determined in accordance with GAAP. Readers should consider non-GAAP measures used in this release in addition to, not as a substitute for, financial reporting measures prepared in accordance with GAAP.  These non-GAAP financial measures exclude some, but not all, items that may affect Merit's net income. In addition, they are subject to inherent limitations as they reflect the exercise of judgment by management about which items are excluded. Merit believes it is useful to exclude such expenses in the calculation of non-GAAP earnings per share, non-GAAP gross margin and non-GAAP net income (in each case, as further illustrated in the reconciliation table below) because such amounts in any specific period may not directly correlate to the underlying performance of Merit’s business operations and can vary significantly between periods as a result of factors such as new acquisitions, non-cash expense related to amortization of previously acquired tangible and intangible assets, unusual compensation expenses or expense resulting from litigation or governmental proceedings.  Merit may incur similar types of expenses in the future, and the non-GAAP financial information included in this release should not be viewed as a statement or indication that these types of expenses will not recur.  Additionally, the non-GAAP financial measures used in this release may not be comparable with similarly titled measures of other companies.  Merit urges investors and potential investors to review the reconciliations of its non-GAAP financial measures to the comparable GAAP financial measures, and not to rely on any single financial measure to evaluate Merit’s business or results of operations. Constant Currency Reconciliation Merit’s revenue on a constant currency basis is prepared by translating the current-period reported sales of subsidiaries whose functional currency is other than the U.S. dollar at the applicable foreign exchange rates in effect during the comparable prior-year period.  The constant currency revenue adjustment of $1.3 million for the three-month period ended March 31, 2017 was calculated using the applicable average foreign exchange rates for the three-month period ended March 31, 2016. Core Revenue Merit’s core revenue is defined as reported revenue excluding revenues from the acquisitions of the HeRO® Graft (excluded January 2017 only) and DFINE, Inc. in 2016 and Catheter Connections, Inc. and the critical care division of Argon Medical Devices, Inc. in 2017. Other Non-GAAP Financial Measure Reconciliation The following table sets forth supplemental financial data and corresponding reconciliations of non-GAAP net income and non-GAAP earnings per share to Merit’s net income and earnings per share prepared in accordance with GAAP for the three-month periods ended March 31, 2017 and 2016.  Non-GAAP gross margin is calculated by reducing GAAP cost of sales by amounts recorded for amortization of intangible assets and inventory mark-up related to acquisitions. The non-GAAP income adjustments referenced in the following table do not reflect stock-based compensation expense of approximately $577,000 and $624,000 for the three-month periods ended March 31, 2017 and 2016, respectively. (a) Reflects the tax effect of the non-GAAP adjustments (d) Represents changes in the fair value of contingent consideration liabilities and contingent receivables as a result of acquisitions (e) Costs incurred in responding to an inquiry from the U.S. Department of Justice (f) Represents the bargain purchase gain realized from the acquisition of the critical care division of Argon Medical Devices, Inc. *Represents sales from the acquisitions of Hero in February 2016; DFINE in July 2016; Catheter Connections in 2017; and the critical care division of Argon Medical Devices in 2017 **The constant currency revenue adjustment of $1.3 million for the three-month period ended March 31, 2017 was calculated using the applicable average foreign exchange rates for the three-month period ended March 31, 2016. ABOUT MERIT Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture and distribution of proprietary disposable medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force totaling approximately 290 individuals.  Merit employs approximately 4,500 people worldwide with facilities in South Jordan, Utah; Pearland, Texas; Richmond, Virginia; Malvern, Pennsylvania; Rockland, Massachusetts; San Jose, California; Maastricht and Venlo, The Netherlands; Paris, France; Galway, Ireland; Beijing, China; Tijuana, Mexico; Joinville, Brazil; Markham, Ontario, Canada; Melbourne, Australia; Tokyo, Japan; and Singapore. FORWARD-LOOKING STATEMENTS Statements contained in this release which are not purely historical, including, without limitation, statements regarding Merit's forecasted plans, revenues, net income, financial results or anticipated or completed acquisitions, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties such as those described in Merit's Annual Report on Form 10-K for the year ended December 31, 2016 and subsequent filings with the Securities and Exchange Commission.  Such risks and uncertainties include risks relating to Merit's potential inability to successfully manage growth through acquisitions, including the inability to commercialize technology acquired through completed, proposed or future transactions; product recalls and product liability claims; expenditures relating to research, development, testing and regulatory approval or clearance of Merit's products and risks that such products may not be developed successfully or approved for commercial use; governmental scrutiny and regulation of the medical device industry, including governmental inquiries, investigations and proceedings involving Merit; reforms to the 510(k) process administered by the U.S. Food and Drug Administration; restrictions on Merit's liquidity or business operations resulting from its current debt agreements; infringement of Merit's technology or the assertion that Merit's technology infringes the rights of other parties; the potential of fines, penalties or other adverse consequences if Merit's employees or agents violate the U.S. Foreign Corrupt Practices Act or other laws or regulations; laws and regulations targeting fraud and abuse in the healthcare industry; potential for significant adverse changes in governing regulations; changes in tax laws and regulations in the United States or other countries; increases in the prices of commodity components; negative changes in economic and industry conditions in the United States or other countries; termination or interruption of relationships with Merit's suppliers, or failure of such suppliers to perform; fluctuations in exchange rates;  concentration of a substantial portion of Merit's revenues among a few products and procedures; development of new products and technology that could render Merit's existing products obsolete; market acceptance of new products; volatility in the market price of Merit's common stock; modification or limitation of governmental or private insurance reimbursement policies; changes in healthcare policies or markets related to healthcare reform initiatives; failure to comply with applicable environmental laws; changes in key personnel; work stoppage or transportation risks; introduction of products in a timely fashion; price and product competition; availability of labor and materials; fluctuations in and obsolescence of inventory; and other factors referred to in Merit's Annual Report on Form 10-K for the year ended December 31, 2016 and other materials filed with the Securities and Exchange Commission. All subsequent forward-looking statements attributable to Merit or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Actual results will likely differ, and may differ materially, from anticipated results. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results, and Merit assumes no obligation to update or disclose revisions to those estimates. TRADEMARKS Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Services, Inc., in the United States and other jurisdictions.


Patent
Rockland, Inc. | Date: 2014-06-26

Recombinant B. burgdorferi proteins, representative of the life cycle, are membrane-immobilized to capture antibodies in biological samples. Lateral flow technology incorporating gold colloid deposition results in band visualization indicative of a positive test.


Patent
Rockland, Inc. | Date: 2014-11-07

A member formed of a set of elongated corrugated cardboard plies secured together with a biodegradable adhesive along the lengths thereof and coated with a biodegradable coating which may be stacked to form a support for a portion of an elongated weighty member.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 225.00K | Year: 2014

DESCRIPTION (provided by applicant): Post-transcriptional RNA modification plays an important role in biological processes. For example, adenosines to nosiness or A-to-I editing are most abundant in the central nervous system (CNS) and essential for normalCNS development. Presently, the available reagents for detection, quantitation, or immunoprecipitation of modified RNA are extremely limited. Rockland Immunochemicals is collaborating with Aptagen to develop synthetic antibodies for detection and quantitation of modified RNAs. In Phase I, as a proof-of-principle, high-affinity and target-specific aptamers and aptamer-based detection assays for inosine and N6- methyladenosine containing RNA will be developed. In Phase II, aptamer reagents and assays to morethan 60 RNA modifications known in eukrayotes will be developed. These affinity reagents will be used in microarrays to profile RNA modifications in different mouse CNS disorder models. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE:


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 249.97K | Year: 2013

Medical imaging and targeted therapy are the central components in the clinical management of cancer patients. Rockland Immunochemicals, Inc. is teaming up with Abzyme Therapeutics LLC to develop novel imaging agents that can be used in both cancer diagnosis and targeted therapy. In this phase I proposal, high-affinity camelid single domain antibodies to three cancer biomarkers HER2, EGFR and mesothelin will be developed. The antibodies will be directionally conjugated to near-infrared spectrum fluorescentdyes. Properties of the nanobody, including in vivo clearance, rapid tumor accumulation, in vivo stability and bioavailability, will be investigated in tumor xenograft animal models. In the Phase II, selected antibodies will be conjugated with chelators for radiolabeling with metal radionuclides. Pharmacokinetic, pharmacodynamics, immunogenic and toxicological characteristics of agents will be investigated in animal models to obtain data necessary for filing an Investigational New Drug application. PUBLIC HEALTH RELEVANCE


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 149.87K | Year: 2011

The RON and c-MET signal pathways are critical regulators of cell growth, survival, migration, differentiation, and drug resistance. High levels of activated RON or c-MET have been observed in a number of human cancers. Activation of RON and c-MET by phosphorylation initiates a signal transduction cascade that promotes cancer cell proliferation, invasiveness, apoptotic and drug resistance, and metastasis. A number of anticancer drugs currently in clinical trials are targeting both of of these pathways. Further, the activation state and protein levels of RON and c-MET are good indicators of drug treatment efficacy and cancer cell survival outcome. In Phase I, we will develop a quantitative immunoassay to monitor the phosphorylation state of either RON or GAB1(the target of c-MET) in various activated and unactivated cancer cell lines. The ELISA kit will be manufactured and written SOPs created. In Phase II, we will use the RON or GAB1 kit to measure activation and protein levels in clinical samples from a wide range of cancers and additional PD assays, including studies using drugs that upregulate or downregulate these targets. The availability of RON and GAB1 detection kits will aid clinicians and researchers to monitor these proteins in a number of diseasesand predict the efficacy of cancer treatment.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase II | Award Amount: 999.00K | Year: 2011

In response to this NCI solicitation, Rockland proposes to develop a novel method to assay the pharmacodynamic (PO) properties of anti-cancer small molecules targeting the PI3K/mTOR/AKT signaling pathway by quantitatively and independently measuring the phosphorylation of each unique AKT isoform in a validated multiplex immunoassay. The developed PD-AKT-ELISA would offer improved personalized medicine, whereby physicians would prescribe a dosage according to the pharmacodynamic effects of anti-cancer drugson individual patients, or modify therapeutic modality based on the feedback for each individual Akt isoform. We plan to use a number of anti-cancer drug candidates in this study and to produce reagents, including monoclonal antibodies to measure inactiveand active AKT isoforms suitable for a fit-for-use theranostic quantitative biomarker ELISA for AKT. The PO-AKT-ELISA and associated reagents will be produced, optimized, validated and applied to both solid tumor and soft tumor xenograft tissue. The reagents and validated assay will measure all AKT isoforms in its active and inactive states to fill a need not currently addressed by products or technologies commercially available to researchers and clinicians. The end result will be a multiplex assay thatcan be used by most existing immunoassay readers in both a research and high through-put clinical environment. Assay results will allow physicians to more precisely target dosages or types of drugs that modulate the PI3K/mTOR/AKT pathway, and will ultimately lower treatment costs by more accurately prescribing effective doses of anticancer drugs and potentially shortening the duration of drug treatment regimens.

Loading Rockland, Inc. collaborators
Loading Rockland, Inc. collaborators